Form 4 for CRL Charles River Laboratories
Accepted 2024-05-15 00:00:00 ET · period of report 2024-05-13 · accession 0001127602-24-015523 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-05-15 | 2024-05-13 | CRL | Kemps-Polanco Reshema | Dir | A - Grant | $228.41 | +844 | 729 | New | +$192.8K |
| D | 2024-05-15 | 2024-05-13 | CRL | Kemps-Polanco Reshema | Dir | A - Grant | $228.41 | +1,311 | 1,311 | New | +$299.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-13 | A | A | 285 | $228.41 | 1,014 | D | — | — | (F2) The grant was made in lieu of director service fees for the term commencing May 8, 2024. The restricted stock units vest upon the earlier of 5/13/2025, or the business day prior to the Company's next annual meeting of shareholders. |
| 2 | Common | Common Stock | 2024-05-13 | A | A | 559 | $228.41 | 729 | D | — | — | (F1) The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. |
| 3 | Derivative | Stock Options (Right to Buy) | 2024-05-13 | A | A | 1,311 | $228.41 | 1,311 | D | $228.41 · 2025-05-13 to 2034-05-13 | 1,311 Common Stock | (F3) The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. |